MPM BioVentures 2014, L.P. - Oct 12, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
Stock symbol
ITOS
Transactions as of
Oct 12, 2021
Transactions value $
-$1,544,474
Form type
4
Date filed
10/14/2021, 05:27 PM
Previous filing
Oct 12, 2021
Next filing
Oct 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale -$231K -8.52K -0.27% $27.09 3.2M Oct 12, 2021 See Footnote F1, F2, F3, F4
transaction ITOS Common Stock Sale -$568K -20.9K -0.65% $27.13 3.18M Oct 13, 2021 See Footnote F1, F5, F6, F7
transaction ITOS Common Stock Sale -$746K -27.3K -0.86% $27.30 3.15M Oct 14, 2021 See Footnote F1, F8, F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
F2 The shares were sold as follows: 5,077 by MPM BioVentures 2014, L.P. ("BV 2014"), 175 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 3,206 by MPM BioVentures 2018, L.P. ("BV 2018") and 63 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The shares are held as follows: 1,810,238, by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 62,305 by AM BV2014, 1,143,307 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 22,563 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
F5 The shares were sold as follows: 12,469 by BV 2014, 429 by AM BV2014, 7,875 by BV 2018 and 156 by AM BV2018.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The shares are held as follows: 1,797,769 by BV 2014, 107,713 by BV 2014(B), 61,876 by AM BV2014, 1,135,432 by BV 2018, 54,213 by BV 2018(B) and 22,407 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F8 The shares were sold as follows: 16,277 by BV 2014, 560 by AM BV2014, 10,280 by BV 2018 and 203 by AM BV2018.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 The shares are held as follows: 1,781,492 by BV 2014, 107,713 by BV 2014(B), 61,316 by AM BV2014, 1,125,152 by BV 2018, 54,213 by BV 2018(B) and 22,204 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.